eTheRNA
Manufacturing · Belgium · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Galileilaan 19, Niel, Flanders, 2845, Be...Phone Number
+32 33691740Website
www.etherna.beRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About eTheRNA
eTheRNA, founded in 2013 and headquartered in Flanders, Belgium, is a clinical-stage Belgian biotech company applying mRNA-based immunotherapies to the treatment of cancer and infectious diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is eTheRNA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if eTheRNA had a recent Job posting/layoffs
Product Launch: Get notified when eTheRNA launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at eTheRNA
Earning: See what the market has to say on eTheRNA recently announced quarterly report
eTheRNA, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once eTheRNA has new funding data
Check out if eTheRNA is spiking on competitors!
Check if eTheRNA has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined eTheRNA as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
eTheRNA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
eTheRNA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about eTheRNA.
eTheRNA financials insights
Gather financial insights about eTheRNA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$26.7M
2022
Series B
$77M
eTheRNA Tech Stack
A closer look at the technologies used by eTheRNA
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Person-Based
Open Position
Executive Move
Executive Moves, Board of Directors
Event
Events
eTheRNA News & Media
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
BARCELONA, Spain & NIEL, Belgium--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermmRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
Sagaert's CEO appointment follows his successful interim period implementing etherna's new partnership-driven business strategy. Sagaert joined etherna in 2017 and brings extensive operational and strategic experience in the life sciences industry. Dekkers, who is the founder of...Steffen Helmling joins etherna as Chief Business Officer
Combines strong US business development track record with in-depth mRNA expertise Global remit with focus on growth of etherna's portfolio of partners Integrated offering key differentiator – Proprietary customized RNA chemistry and lipid nanoparticles (cLNPs) expertise combined with GMP...Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins Etherna as independent board member
NIEL, Belgium, Jan. 9, 2023 /PRNewswire/ -- Etherna ("the Company"), a leading mRNA technologies company, announced today that Antonin (Tony) de Fougerolles has joined its board of directors as an independent member. This follows the Company's recent Series B2 financing round to expand...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding eTheRNA
Sign Up For FreeTo access detailed company insights
eTheRNA, founded in 2013 and headquartered in Flanders, Belgium, is a clinical-stage Belgian biotech company applying mRNA-based immunotherapies to the treatment of cancer and infectious diseases.... Read More
